Avastin Articles
Stock Commentary - New York week to March 30, 2009
2 April 2009
EMEA Avastin label
1 April 2009
Japan stock market week to March 30, 2009
31 March 2009
Sutent cleared for UK kidney cancer patients
30 March 2009
Cilengitide "promotes cancer growth"
30 March 2009
Genentech accepts Roche $95/share bid
16 March 2009
Roche upped bid still gets Genentech's "no"
16 March 2009
PDL returns to profit on sales up 31%
16 March 2009
Genentech advises shareholders to reject Roche's $86.50 per share bid; growing hostility
2 March 2009
Japan stock market week to Feb 9, 2009
16 February 2009
Sutent available in England, not Scotland
9 February 2009
Roche's profit falls 5% on lower Tamiflu sales
9 February 2009
OSI shares jump 11.4% on Tarceva/Avastin benefit in NSCLC
9 February 2009
Roche files Avastin in Europe for glioblastoma
22 December 2008
Japan stock market week to Dec 1, 2008
8 December 2008
Avastin increases PFS in advanced breast cancer
1 December 2008
Avastin sBLA submitted for glioblastoma
17 November 2008
Ph III Avastin gets interim DMC go-ahead
27 October 2008
Tarceva plus Avastin miss Ph III endpoint
13 October 2008
Idera reports first data from carcinoma trial
6 October 2008
Top-20 cancer therapy brands market report from C&M
6 October 2008
Japan stock market week to Sept 15, 2008
22 September 2008
Pfizer economic study says Sutent cost effective in mRCC
22 September 2008
UK
15 September 2008
Rx drug prices "double" US political impact
18 August 2008
UK cancer charity slams NICE methods
11 August 2008
EU's pediatric drug c'tee celebrates first birthday
28 July 2008
Roche's 1st-half net profit sees downturn
28 July 2008
Avastin plus Sutent trial ended on anemia fears
21 July 2008
Roche
7 July 2008
Stock Commentary - New York week to June 2, 2008
9 June 2008
Avastin + Herceptin HER2 study initiated
9 June 2008
Roche to lift stake in Chugai to 59.9%
2 June 2008
Stock Commentary - New York week to April 21, 2008
28 April 2008
Stock Commentary - Europe - week to April 21, 2008
28 April 2008
Roche's Avastin fails to show overall survival
28 April 2008
Amgen's AMG 386 aids tumor growth reduction
21 April 2008
Positive outlook for AstraZeneca's Recentin
7 April 2008
Japan stock market week to March 17, 2008
24 March 2008
Avastin to become new standard for HER2 MBC
17 March 2008
Japan stock market week to March 10, 2008
17 March 2008
Stock Commentary - Europe - week to March 3, 2008
10 March 2008
Strong early data on Davanat plus 5-FU in CRC
10 March 2008
Everolimus trial halted after early PFS gains
10 March 2008
Stock Commentary - Europe - week to Feb 25, 2008
3 March 2008
Stock Commentary - New York week to Feb 25, 2008
3 March 2008
Mixed Ph II data on AstraZeneca's Recentin
3 March 2008
Japan stock market week to Feb 25, 2008
3 March 2008
Mixed Ph II data on AstraZeneca's Recentin
3 March 2008
UK's NHS denies care to top-up patients
3 March 2008
Tokyo stocks in the week to February 18, 2008
25 February 2008
Avastin improves PFS in breast cancer
25 February 2008
EC grants Xeloda broad approval for mCRC
11 February 2008
Stock Commentary - New York week to Jan 28, 2008
4 February 2008
EC broadens Avastin use in mCRC indication
4 February 2008
Roche's Avastin launched in UK for RCC
28 January 2008
UK row over ban on NHS patients buying drugs
7 January 2008
Avastin shows good safety profile in Ph II breast cancer trial
24 December 2007
Xeloda and Avastin to get expanded indications
24 December 2007
Stock Commentary - Europe - week to Dec 10, 2007
17 December 2007
Stock Commentary - New York week to Dec 3, 2007
10 December 2007
Stock Commentary - Europe - week to Dec 3, 2007
10 December 2007
ODAC
10 December 2007
Driven by Avastin, ovarian cancer market set to reach $1.6B by 2016
10 December 2007
Most UK NHS patients not told of drug options
26 November 2007
CHMP OKs Roche's Avastin for RCC
26 November 2007
Genentech's 3rd-qtr income climbs 21% with sales of $2.9B; but analysts question reliance on Avastin
22 October 2007
Genentech to curtail off-label Avastin use
22 October 2007
Stock Commentary - New York week to Oct 8, 2007
15 October 2007
Avastin aids complete resection of mCRC lesions
8 October 2007
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
